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ABSTRACT 
 
This is a prospective case controlled hospital based study done in 
khartoum teaching hospital in the period feb 2004-Aug2004 . 
The aim of the study was to asses the prevalence and clinical 
presentation of Dengue fever and to determine morbidity and 
mortality among febrile patients. 
107 patients of age ranged between (15-60) years and who had fever 
for less than two weeks duration were selected for the study . 
A written consents were obtained from all patients and controls . 
Base line data was collected through a questionnaire that included 
the history of illness and clinical examination for each patient. 
Investigations were done for all patients including blood film for 
malaria ,ICT for malaria, white blood count and urine analysis . 
All pateints and control were tested for IgG and IgM antibodies 
against Dengue virus by rapid test. 
Significant immuogobulim M(IgM) was detected in (10.28%) of the 
study group(febrile patients). 
• No positive result for immuonglobulin G(IgG) against dengue 
virus was detected neither in febrile patients nor in controls. 
The study showed a significant association between presence of I 
gM antbody against Dengue virus and the following symptoms . 
• Fever between (37- 38.5 C) 
• Headache and cough(100%) 
• Myalgia(90.9%) 
• Neck pain(63.3%) 
While diarrhea , retro-orbital pain and photophobia were less likely 
presentation (27.3%). 
Lymphadenopathy (cervical& submandibular) was detected in 
(99%) of the study group and in all IgM positive patients suggesting 
other infections beside Dengue fever . 
No haemorrhagic signs were detected in the study and all patients 
recovered in 1-2 weeks with only supportive treatment.  
 
 
 
 
   
  ﻣﻠﺨﺺ اﻻﻃﺮوﺣﺔ
 4002هﺬﻩ دراﺳﺔ ﻣﺴﺘﻘﺒﻠﻴﺔ ﻣﺘﺤﻜﻢ ﺑﻬﺎ اﺟﺮﻳﺖ ﻓﻲ ﻣﺴﺘﺸﻔﻲ اﻟﺨﺮﻃﻮم اﻟﺘﻌﻠﻴﻤﻲ ﻓﻲ اﻟﻔﺘﺮة ﻣﻦ ﻓﺒﺮاﻳﺮ 
  . م4002وﺣﺘﻲ اﻏﺴﻄﺲ 
اﻟﻬﺪف ﻣﻦ اﻟﺪراﺳﺔ ﻣﻌﺮﻓﺔ ﻣﻌﺪل اﻧﺘﺸﺎر ﻣﺮض ﺣﻤﻲ اﻟﻀﻨﻚ اﻟﻮﻓﻴﺎت واﻻﻣﺮاﺿﻴﺔ وﻣﻌﺮﻓﺔ ﺣﺎﻟﺘﻪ 
  .اﻟﺴﺮﻳﺮﻳﺔ اﻟﻤﺨﺘﻠﻔﺔ 
 ﻋﺎﻣًﺎ وﻳﻌﺎﻧﻮن ﻣﻦ 06-51ﻟﺬﻳﻦ ﺗﺘﺮاوح اﻋﻤﺎرهﻢ ﺑﻴﻦ  ﺣﺎﻟﺔ ﻣﻦ اﻟﻤﺮﺿﻲ ا701ﺣﻴﺚ ﻗﻤﺖ ﺑﺪراﺳﺔ 
اﻟﺤﻤﻲ ﻟﻔﺘﺮة اﻗﻞ ﻣﻦ اﺳﺒﻮﻋﻴﻦ ﻣﻊ اﺳﺘﺒﻌﺎد اي اﺳﺒﺎب اﺧﺮي ﻟﻠﺤﻤﻲ ،وآﺬﻟﻚ ﺗﻢ ﺟﻤﻊ اﻟﻌﻴﻨﺎت ﻣﻦ 
  . اﺷﺨﺎص ﻻﻳﻌﺎﻧﻮن ﻣﻦ اﻟﺤﻤﻲ 701
ﺗﻢ ﺟﻤﻊ اﻟﻤﻌﻠﻮﻣﺎت ﺑﻌﺪ ﻣﻞ اﻗﺮار ﻣﻜﺘﻮب ﻋﻦ ﻃﺮﻳﻖ ﺗﻌﺒﺌﻪ اﺳﺘﻤﺎرة اﺳﺘﺒﻴﺎن ﺷﺎﻣﻠﺔ ﻋﻠﻰ اﻟﺘﺎرﻳﺦ 
ﺺ اﻟﺴﺮﻳﺮي ﻟﻜﻞ ﺣﺎﻟﺔ ﺑﺎﻻﺿﺎﻓﺔ اﻟﻲ اﺧﺬ ﺛﻼﺛﻪ ﻣﻞ دم ﻣﻦ آﻞ ﻣﺮﻳﺾ ﻻﺟﺮاء اﻟﻤﺮﺿﻲ واﻟﻔﺤ
 ﻟﻠﻤﻼرﻳﺎ ، اﻟﺪم اﻻﺑﻴﺾ ، ﺗﺤﻠﻴﻞ اﻟﺒﻮل،  TCIاﻟﻔﺤﻮﺻﺎت اﻟﻤﻌﻤﻠﻴﺔ اﻟﺨﺎﺻﺔ ﻣﺜﻞ اﻟﺪم ﻟﻠﻤﻼرﻳﺎ 
ﻋﻦ ﻃﺮﻳﻖ " م"و" ج"ﻻﺳﺘﺒﻌﺎد ﺑﻌﺾ اﻧﻮاع اﻟﺤﻤﻲ ﺗﻢ ﻓﺤﺺ ﻋﻴﻨﺎت اﻟﺪم ﻟﻤﻀﺎدات ﻣﻨﺎﻋﻴﺔ  اﻟﻔﻴﺮوس 
  . اﻟﻔﺤﺺ اﻟﺴﺮﻳﻊ 
ﻣﻦ ﻣﺠﻤﻮع اﻟﺪراﺳﺔ وﻟﻢ ﺗﻮﺟﺪ اي % 82.01ﻳﻤﺜﻞ " م" وﺟﻮد اﻟﻤﻀﺎدات اﻟﻤﻨﺎﻋﻴﺔ ﻣﻦ ﻧﻮع ﻧﺴﺒﺔ
ﻓﻲ اي ﻣﻦ اﻟﻤﺠﻤﻮﻋﺘﻴﻦ ﻣﻤﺎ ﻳﺪل اﻟﻲ ان ﻓﻴﺮوس " ج"ﻧﺘﻴﺠﺔ اﻳﺠﺎﺑﻴﺔ ﻟﻤﻀﺎدات اﻟﻤﻨﺎﻋﺔ ﻣﻦ ﻧﻮع 
  .اﻟﻌﺪوي اﻻوﻟﻴﺔ اآﺜﺮ ﺣﺪوﺛﺎ ﻣﻦ اﻟﻌﺪوي اﻟﺜﺎﻧﻮﻳﻪ ﻓﻲ هﺬﻩ اﻟﺪراﺳﺔ
ﺿﺪ ﻓﻴﺮوس اﻟﻄﻨﻚ " م"اﻳﺠﺎﺑﻴﺔ اﻟﺒﺮوﺗﻴﻦ اﻟﻤﻨﺎﻋﻲ اوﺿﺤﺖ اﻟﺪراﺳﺔ وﺟﻮد ﻋﻼﻗﺔ وﻃﻴﺪة ﺑﻴﻦ 
  -:واﻻﻋﺮاض اﻻﺗﻴﺔ 
  (. درﺟﺔ ﻣﺌﻮﻳﺔ83-73)اﻟﺤﻤﻲ ﺑﻴﻦ  •
 %(001)واﻟﻢ اﻟﺮاس واﻟﺴﻌﺎل  •
 %(9.09)اﻟﻢ اﻟﻌﻀﻼت •
 %(3.36)اﻟﻢ اﻟﺮﻗﺒﺔ •
ﻣﻦ ﺿﻤﻦ اﻻﻋﺮاض %( 3.72)ﺑﻴﻨﻤﺎ اﻟﺴﻬﺎل واﻟﻢ ﺧﻠﻒ اﻟﻌﻴﻨﻴﻦ وﻋﺪم ﺗﺤﻤﻞ اﻟﻀﻮء ﺗﻤﺜﻞ 
ﺗﺸﺨﻴﺺ اﻟﺤﺎﻻت ﻓﻲ هﺬﻩ اﻟﺪراﺳﻪ، ﻟﻮﺣﻆ اﻳﻀًﺎ ان ﺣﺪوث ﺗﻀﺨﻢ اﻟﻤﺤﺘﻤﻠﺔ وهﻲ اﻗﻞ اهﻤﻴﺔ ﻓﻲ 
وآﺬﻟﻚ اﻳﺠﺎﺑﻴﺎ % ( 99) ﺑﻨﺴﺒﺔ ﻋﺎﻟﻴﺔ ﻓﻲ ﻣﺠﻤﻮﻋﺔ اﻟﺪراﺳﺔ( اﻟﺮﻗﺒﺔ وﺗﺤﺖ اﻟﻔﻚ ) اﻟﻐﺪد اﻻﻟﻤﻔﻴﺔ 
   
، ﻣﻤﺎ ﻳﺰﻳﺪ اﺣﺘﻤﺎﻟﻴﺔ " م"اﻳﺠﺎﺑﻴﺔ ﻣﻀﺎدات اﻟﺪم اﻟﻤﻨﺎﻋﻴﺔ ﻣﻦ ﻧﻮع%( 001)ﻓﻲ آﻞ اﻟﻤﺠﻤﻮﻋﺔ 
  .اﻻﺳﺒﺎب اﻻﺧﺮي ﻟﻠﺤﻤﻴﺎت ﺣﺪوث ﺗﻀﺨﻢ هﺬﻩ اﻟﻐﺪد ﻣﻊ ﺣﻤﻲ اﻟﻀﻨﻚ و
 .ﻟﻢ ﺗﻼﺣﻆ اي اﻋﺮاض ﻧﺰﻓﻴﺔ ﻓﻲ ﻣﺠﻤﻮﻋﺔ اﻟﺪراﺳﺔ  •
 اﺳﺒﻮع دون 2-1آﻞ اﻟﻤﺮﺿﻲ زاﻟﺖ اﻟﺤﻤﻲ واﻻﻋﺮاض ﺧﻼل ﻣﺪة ﺗﺘﺮاوح ﺑﻴﻦ  •
  .ﻋﻼﺟﺎت
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
Chapter One 
1-  INTRODUCTION 
 
Dengue causes more illness and death than any other 
arboviral infection, there are at least 20 million infections in the world 
each year and several hundred thousand cases of a severe, life-
threatening syndrome known as dengue haemorrhagic fever/dengue 
shock syndrome (DHF/DSS).                   
In recent years, the geographical range of dengue has 
extended and DHF/DSS is occurring in new areas and with increased 
incidence. The reasons for the resurgence are complex, but parallel 
demographic changes and reduced efforts towards disease control.1 
 
 
 
 
 
 
   
 
2- LITERATURE REVIEW 
 
Dengue Viral Fever: 
Dengue virus (DV) is the causative agent of dengue fever (DF) 
and dengue hemorrhagic fever (DHF) and consists of four distinct 
serotypes (DEN-1, DEN-2, DEN-3, and DEN-4). 2   Symptoms include 
sudden onset of fever, intense headache, and muscle and lower back 
pain. The duration of illness is usually 1–2 weeks. During the 1995 
outbreak in Palau, disease was mild and hemorrhagic manifestations 
were rare. Although the symptoms associated with dengue 4 virus 
infections have been reported as being milder than symptoms 
associated with infections with the other subtypes (with outbreaks 
being characterized by a majority of dengue fever rather than dengue 
hemorrhagic fever), infections with dengue 4 virus can also be 
associated with severe and fatal disease. 3   DHF, the potentially fatal 
form of dengue virus infection, was first recognized in Bangkok, 
Thailand, in 1958. Since then, dengue disease incidence has 
increased from 9/100,000 in 1958 to 189/100,000 in 1998, with the 
   
largest reported incidence of 325/100,000 in 1987. Dengue has thus 
become a severe and intractable public health problem in Thailand.  2      
         Dengue haemorrhagic fever (DHF) first emerged as a public 
health problem in 1954, when the first epidemic occurred in Manila. 
This gradually spread to other countries in the region. Major 
epidemics occurred in other regions of the world in the 1980s and 
1990s and were caused by all four dengue viral serotypes. While the 
predominant serotype in the 1980s and the early 1990s was DEN-2, 
in recent years it has changed to the DEN-3 serotype.                       
In 1998, a pandemic of dengue viral infections occurred, where 1.2 
million cases of dengue fever and DHF were reported from 56 
countries worldwide. The world population was exposed to a new 
subtype of the DEN-3 virus (subtype III), which originated in the 
Indian subcontinent and later spread to involve other continents. 
Exposure of a non-immune population to this new subtype of DEN-3 
may have been the cause of this pandemic. A situation of comparable 
magnitude was also seen in 2001–02. 4 In most of the tropical and 
subtropical world, dengue fever is a leading cause of morbidity and 
mortality, particularly among children. 3        
   
  In the last four decades the incidence of dengue fever has 
increased 30-fold worldwide, and over half the world's population is 
now threatened with infection from one or more of four co-circulating 
viral serotypes (DEN-1 through DEN-4). 5                 
 
Clinical Epidemiology:    
During the 19th century, dengue was considered a sporadic 
disease, causing epidemics at long intervals. However, dramatic 
changes in this pattern have occurred and currently, dengue ranks as 
the most important mosquito borne viral disease in the world. In the 
past 50 years, its incidence has increased 30-fold with significant 
outbreaks occurring in five of six World Health Organisation (WHO) 
regions. At present, dengue is endemic in 112 countries in the world. 
Around 2.5 to 3 billion people, living mainly in urban areas of 
tropical and subtropical regions, are estimated to be at risk of 
acquiring dengue viral infections. Estimates suggest  that annually 
100 million cases of dengue fever and half a million cases of dengue 
haemorrhagic fever (DHF) occur in the world with a case fatality in 
Asian countries of 0.5%–3.5%. Of those with DHF, 90% are children 
less than 15 years of age. 6 Although the mosquito vector and all four 
   
dengue viral serotypes are present in the African region, to date an 
epidemic of DHF has not occurred. Since DHF is less frequent 
among black persons living in areas that experience epidemics of 
DHF, it is possible that individuals of African origin may have a 
degree of inherent resistance to the disease.3 Dengue is an acute 
febrile disease caused by infection  with any of four serotypes of 
dengue virus (DEN), a flavivirus. It is a public health problem of 
growing importance in areas where the insect vector, Aedes aegypti 
and related species, is abundant. Although most DEN infections 
present as a benign illness with low mortality, many countries report 
increasing incidences of severe manifestations, i.e. dengue 
haemorrhagic fever (DHF) and dengue shock syndrome (DSS). DEN 
infections have been identified as a cause of febrile illness in 
travellers. The clinical-to-subclinical infection rate was 1 :3.3. The risk 
of infection showed marked seasonal variation. DEN infections are 
frequent in travellers to endemic areas in Asia; most remain 
subclinical. 45% of cases of fever in travellers returning from endemic 
areas.6 
Depending on the population studied and the laboratory 
methods used, serological evidence of recent DEN infection was 
   
found in 7  45% of cases of fever in travellers returning from endemic 
areas. Mechanisms of disease transmission in human outbreaks of 
HFVs are still poorly  understood.  Clarification of the role of  airborne  
transmission is vital. Rapid diagnostic methods need to be developed 
for all of the HFVs. Methods to safely handle potentially infected 
specimens in a clinical laboratory should be developed. 7 
 
Characteristics of Dengue Virus:  
The dengue virus is a single stranded RNA virus belonging to 
the flaviviridae family.There are four serotypes (DEN 1–4), classified 
according to biological and immunological criteria. The viral genome 
is approximately 11 kb in length. The mature virion consists of three 
structural (core, membrane associated, and envelope) and seven 
non-structural (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5) 
proteins. The envelope protein is involved in the main biological 
functions of the virus. It binds to receptors on host cells, allowing the 
virus to be transported through it. In addition, the envelope protein is 
associated with haemagglutination of erythrocytes, induction of 
neutralising antibodies and protective immune responses. 4  Non-
structural proteins (NS1–NS5) expressed as both membrane 
   
associated and secreted forms have also been implicated in the 
pathogenesis of severe disease. Unlike other viral glycoproteins, NS1 
does not form a part of the virion but gets expressed on the surface of 
infected cells. Preliminary evidence suggests its involvement in viral 
RNA replication. Plasma levels of secreted NS1 (sNS1) correlate with 
viral titres, being higher in patients with DHF compared with dengue 
fever. Moreover, elevated free sNS1 levels within 72 hours of onset of 
illness identify patients at risk of developing DHF. Very high levels of 
NS1 protein are detected in acute phase samples from patients with 
secondary dengue infections but not primary infections. This suggests 
that NS1 may contribute to formation of circulating immune 
complexes, which are thought to have an important role in the 
pathogenesis of severe dengue infections.  
The dengue virus shares antigenic epitopes with other 
flaviviruses such as Japanese encephalitis virus. These shared 
epitopes may lead to production of cross reactive antibodies and 
hence interfere with serological diagnosis. However, antibodies 
directed to the prM protein of dengue viruses are species specific (not 
cross reactive with those of other flaviviruses) and may be useful for 
   
sero epidemiological studies in dengue (especially in countries where 
other flaviviruses are endemic). 4 
 
Clinical Manifestations Of Dengue Infection: 
The clinical features of dengue vary with the age of the patient 
and, in addition to clinically inapparent infections, can be classified 
into five presentations: non-specific febrile illness, classic dengue, 
dengue haemorrhagic fever, dengue haemorrhagic fever with dengue 
shock syndrome, and other unusual syndromes such as 
encephalopathy and fulminant liver failure. 8 Young children with 
dengue often have an undifferentiated febrile illness with a 
maculopapular rash. Upper respiratory infections, especially 
pharyngitis, are common. Most infections in children under 15 years 
are asymptomatic or minimally symptomatic; a study of 
schoolchildren in Thailand found only 13% of those infected missed 
more than one day of school because of illness. Classic dengue is 
more commonly seen among older children, adolescents, and adults. 
They are less likely to be asymptomatic. Dengue is abrupt in onset, 
typically with high fever accompanied by severe headache, 
incapacitating myalgias and arthralgias, nausea and vomiting, and 
   
rash. Rash, typically macular or maculopapular, often becoming 
confluent and sparing small islands of normal skin, has been reported 
in over half of infected people. Other signs and symptoms include 
flushed facies, sore throat, cough, cutaneous hyperaesthesia, and 
taste aberrations. Recovery may be prolonged and include 
depression. 9 
 
Undifferentiated Fever:  
  This usually follows a primary infection but may also occur 
during a secondary infection. 4 Most dengue viral infections are 
clinically inapparent or result in a mild, flu-like (viral syndrome) illness, 
particularly in young children. The incubation period ranges from 3 to 
14 days (average = 4–7 days) 1 Dengue fever, may present as a 
spectrum of illness that ranges from asymptomatic infection to severe 
hemorrhagic diathesis. Most dengue viral infections are clinically 
inapparent or result in a mild, flu-like (viral syndrome) illness, 
particularly in young children. Risk factors that influence disease 
severity include the strain of virus, and the age, immune status, and 
genetic background of the host. The incubation period ranges from 3 
to 14 days (average = 4–7 days) 10     
   
 
 
Dengue Fever:    
Dengue fever may occur either during primary or secondary 
infections. 4  Patients with DF could not be distinguished from other 
febrile patients on clinical grounds alone. 9    Infection results in a 
viremia that lasts from 2 to 12 days (average = 5 days).  Generally, 
older children and adults more frequently experience classic dengue 
fever, an acute febrile illness of several days’ duration. 5 The onset is 
sudden with high fever, severe headache (especially in the retro-
orbital area), arthralgia, myalgia, anorexia, abdominal discomfort, and 
sometimes a macular papular rash. The fever may be biphasic and 
tends to last for 2–7 days. Flushing, a characteristic feature is 
commonly observed on the face, neck, and chest. Coryza may also 
be a prominent symptom especially in infants. Younger children tend 
to present with coryza, diarrhoea, rash and seizure, and less 
commonly with vomiting, headache, and abdominal pain. Although, 
haemorrhagic manifestations are uncommon in dengue fever, 
petechiae / pupura, gastrointestinal bleeding, epistaxis, and gingival 
bleeding have been observed in some individuals. A positive 
   
tourniquet test has been reported in many individuals with dengue 
fever possibly due to reduced capillary fragility. Recovery from 
dengue fever is usually uneventful, but may be prolonged especially 
in adults.4 In a large prospective study of pediatric dengue, no clinical 
or basic laboratory parameters clearly differentiated between children 
with and without dengue, although petechiae and hepatomegaly were 
independently associated with the diagnosis.11 Dengue fever (DF) 
with acute acalculous cholecystitis is rarely reported.12                                    
 
Dengue Haemorrhagic Fever:  
DHF usually follows secondary dengue infections, but may 
sometimes follow primary infections, especially in infants. In such 
infants, maternally acquired dengue antibodies are presumed to 
enhance primary infections. Such a phenomenon has not been 
described in human infections other than dengue. 4 Dengue 
haemorrhagic fever is primarily a disease of children under 15 years 
in hyperendemic areas. Black populations may be at decreased risk. 
The disease is characterised by increased capillary permeability and 
haemostatic changes. If major plasma leakage occurs, it usually 
develops 24 hours before to 24 hours after defervescence. Patients 
   
may develop effusions and ascites with a variable amount of 
bleeding. Enlargement and tenderness of the liver has been reported 
in up to 40% of patients. Mortality can be as high as 10-20% (over 
40% if shock occurs) without early appropriate treatment, but it is as 
low as 0.2% in hospitals with staff experienced in the disease. 
Warning signs that dengue shock syndrome is impending include 
sustained abdominal pain, persistent vomiting, change in level of 
consciousness (irritability or somnolence), a sudden change from 
fever to hypothermia, and a sudden decrease in platelet count. Rare 
presentations of infection include severe haemorrhage, jaundice, 
parotitis, and cardiomyopathy. Unusual neurological presentations 
include mononeuropathies, polyneuropathies, encephalitis, and 
transverse myelitis. Guillain-Barré syndrome has been associated 
with dengue. Encephalopathy occurs occasionally and may result 
from cerebral oedema, cerebral haemorrhage, liver failure, or 
electrolyte imbalances. Laboratory findings commonly associated 
with dengue include neutropenia, lymphocytosis, increased 
concentration of liver enzymes, and thrombocytopenia. Diagnosis can 
be confirmed with several laboratory tests; most often the 
haemagglutination inhibition test and IgG or IgM enzyme 
   
immunoassays. The non-specific presentation and course of infection 
underscore the importance of laboratory testing for confirmation of 
cause. Several diseases should be considered in the differential 
diagnosis 13 
 
Dengue Shock Syndrome:   
Dengue shock syndrome is associated with very high mortality 
(around 9.3%, increasing to 47% in instances of profound shock). 
Severe plasma leakage leading to dengue shock syndrome is 
associated with cold blotchy skin, circumoral cyanosis, and circulatory 
disturbances. Acute abdominal pain and persisting vomiting are early 
warning signs of impeding shock. Sudden hypotension may indicate 
the onset of profound shock. Prolonged shock is often accompanied 
by metabolic acidosis, which may precipitate disseminated 
intravascular coagulation or enhance ongoing disseminated 
intravascular coagulation, which in turn could lead to massive 
haemorrhage. Dengue shock syndrome may be accompanied by 
encephalopathy due to metabolic or electrolyte disturbances.4 
Rhabdomyolysis is not well described as a complication of dengue 
virus infection and is probably underrecognized. All patients with 
   
severe dengue virus infection should undergo urinalysis, and serum 
creatinine kinase levels should be measured if urinalysis reveals 
heme.14  Ocular complications associated with dengue fever are rare 
but may result in permanent visual impairment. 15   
Acute acalculous cholecystitis Found in a small proportion of patients 
with DF. 16 
 
Dengue Fever in Pregnancy:  
More cases of dengue infection in pregnancy can be found 
because of the increasing incidence of dengue infection among 
adults. The infection should be suspected when a pregnant woman 
presents with the similar pattern of symptoms and signs like in a non-
pregnant case. Conservative treatment should be given unless there 
are complications. 17 
 
Mosquitoes Vectors in Dengue Infections:  
Mosquitoes belonging to the genus aedes (Aedes aegypti, 
Aedes albopictus, and Aedes polynesiensis) play an important part in 
transmission of dengue. The primary and most important vector is A 
.aegypti, but A albopictus and A polynesiensis may act as vectors 
   
depending on the geographic location. For instance, A albopictus has 
been found to sometimes transmit dengue in Thailand, Samui island, 
India, Singapore, and Mexico. Aedes aegypti, a container breeding, 
day biting mosquito is found in tropical and subtropical areas. They 
rest indoors, mainly in living rooms and bedrooms. This maximises 
man-vector contact and minimises contact with insecticides sprayed 
out doors, hence contributing to difficulty in controlling this vector. 
Aedes aegypti can breed in polluted water or small collections of 
water such as flower vases or coconut shells. Eggs can survive for 
long periods, as they are capable of withstanding desiccation. 4 
Humans and mosquitoes are the principal hosts of dengue virus; the 
mosquito remains infected for life, but the viruses are only known to 
cause illness in humans.8 Improper disposal of garbage or 
inadequate wastewater drainage facilitates, both consequences of 
unplanned urbanisation, may be responsible for high mosquito 
densities in endemic areas. Significant increases in the mosquito 
larval populations are seen during the rainy season. This may be a 
reason why epidemics of dengue tend to coincide with the rainy 
season. Furthermore, ambient temperature and relative humidity 
affect viral propagation in mosquitoes rates being highest in climates  
   
resembling the rainy season. Environmental temperatures also 
affect the time to acute viraemia in female mosquitoes, being shorter 
with rises in temperature. 4  After biting an infected human, dengue 
viruses enter an adult female mosquito. The virus first replicates in 
the midgut, reaches the haemocoel and haemolymph, and then gains 
access to different tissues of the insect. After viral replication in the 
salivary glands, the infected mosquito can transmit the virus to 
another human. Ultrastructural studies show viral particles within the 
nervous system, salivary glands, foregut, midgut, fat body, epidermal 
cells, ovary and internal body wall lining cells of the mosquito. In 
contrast, they are absent from muscle, the hindgut, and malphigian 
tubules. Compared with uninfected mosquitoes, infected ones take 
longer to complete a blood meal. This may contribute to the efficiency 
of A aegypti as a dengue viral vector. This increased time 
corresponds to dengue virus infection of organs known to control or 
influence activities associated with feeding. 4 
 
Pathogenesis of Dengue Fever/ Dengue Haemorragic 
Fever:      
   
Several studies suggest the existence of transovarial dengue 
virus transmission in aedes infected female mosquitoes, allowing 
propagation of virus to their progeny. Such a process would allow it to 
act as a reservoir for virus maintenance during interepidemic periods 
(without human or other vertebral host participation). Reports also 
suggest that dengue viruses may be transmitted sexually from the 
male to female mosquitoes, but not vice versa. 4 Dengue 
haemorrhagic fever is distinguished from dengue by the presence of 
increased vascular permeability, not by the presence of 
haemorrhage. Patients with dengue may have severe haemorrhage 
without meeting WHO criteria for dengue haemorrhagic fever. In 
these cases the pathogenesis probably derives from 
thrombocytopenia or a consumptive coagulopathy, not from the 
vascular leak syndrome seen in dengue haemorrhagic fever. Dengue 
haemorrhagic fever may (grades III and IV) or may not (grades I and 
II) include clinical shock, referred to as dengue shock syndrome. 
Dengue virus antigen has been found in a variety of tissues, 
predominately the liver and reticuloendothelial system. Viral 
replication is thought to occur primarily in the macrophages, although 
dendritic cells (Langerhans cells) in the skin may be an early target of 
   
infection. As with yellow fever, focal central necrosis has been found 
in the liver of patients who have died of dengue. Autopsies of patients 
who died of dengue haemorrhagic fever show diffuse petechial 
haemorrhages in most organs and serous effusions of pericardial, 
peritoneal, and pleural spaces. Dengue virus (by isolation and 
reverse transcription-polymerase chain reaction) and antibody 
(including IgM) have been identified in the cerebrospinal fluid, but 
direct involvement of dengue virus in neuronal damage is 
controversial. More studies on this are needed. All four serotypes 
have been associated with dengue haemorrhagic fever. Variations in 
virus strains within and between the four serotypes may influence 
disease severity. Secondary infections (particularly with serotype 2) 
are more likely to result in severe disease and dengue haemorrhagic 
fever. This is explained by the theory of antibody dependent 
enhancement, whereby cross reactive but non-neutralising antibodies 
from a previous infection bind to the new infecting serotype and 
facilitate virus entry into cells resulting in higher peak viral titres. In 
primary and secondary infections, higher viral titres are associated 
with more severe disease. Higher titres may result in an amplified 
cascade of cytokines and complement activation causing endothelial 
   
dysfunction, platelet destruction, and consumption of coagulation 
factors, which result in plasma leakage and haemorrhagic 
manifestations. 13   
 
 Prognostic Indicators and Outcome:         
The risk of infection was significantly associated with older age, 
low education and low income .Risk factors that influence disease 
severity include the strain of virus, and the age, immune status, and 
genetic background of the host, low education and low income. 3 
When a person has been exposed to one flavivirus, cross-reacting 
antibodies may affect the outcome of infection with a second 
flavivirus. Thus, for patients with Japanese encephalitis, prior 
infection with dengue virus, which circulates through much of Asia, 
appears to protect against severe disease. In contrast, serial infection 
with different serotypes of dengue virus appears to be associated with 
more severe disease (e.g., dengue hemorrhagic fever), possibly 
because of an antibody-dependent enhancement of infection, though 
the strain of dengue virus may also be important. 18 DHF   is also 
reported to be more severe among females. 4 DHF tends to be 
   
commoner among patients suffering from other chronic illnesses (for 
example, diabetes mellitus or bronchial asthma.4 
Case fatality and hospitalization rates due to DHF/dengue 
shock syndrome are highest in infants and the elderly.4 
Predictive markers for DSS were younger age at onset, altered 
sensorium, paralytic ileus, and significantly deranged PT. Patients 
with DSS also had a longer recovery period and required more 
supportive management in the form of component therapy and 
ionotropic support. 19      
        
 Laboratory Diagnosis of Dengue Infections:     
            In most cases of dengue fever, platelet counts and serum 
biochemistry are normal. However, leucopenia, thrombocytopenia, 
and raised liver enzymes may be seen. In contrast, DHF is always 
accompanied by a platelet count <100 x 109/l, haemoconcentration  
(a rise in the packed cell volume >20% of basal levels), leucopenia, 
and raised liver enzymes .Elevation of both alanine and aspartate 
aminotransferase levels occur with plasma aspartate 
aminotransferase levels being higher in children who develop DHF 
than in those with dengue fever. 4  A leucopenia of 5x109/l has been 
   
suggested to predict the onset of DHF. Initial leucopenia is followed 
by a relative lymphocytosis (with more than 15% atypical 
lymphocytes) towards the end of the febrile phase. Abnormal 
coagulation profiles (prolonged partial thromboplastin time and 
prothrombin time, raised fibrinogen degradation products), 
hypoalbuminaemia, and reduced serum complement levels are also 
seen. These coagulation abnormalities suggest that there is activation 
of both coagulation and fibrinolysis during acute infection and the 
degree of activation being greater in severe DHF and dengue shock 
syndrome. 4 In numerous acute dengue fever patients an early 
diagnosis will be obtained only by combining IgM antibody detection 
with detection of virus or virus RNA using RT-PCR. 20 The HFVs 
(including Rift Valley fever and the flaviviruses) are highly infectious 
in the laboratory setting and may be transmitted to laboratory 
personnel via small-particle aerosols. Designated laboratory workers 
should receive training in handling specimens from any suspected 
VHF patients in advance of such an event. Laboratory workers should 
wear personal protective equipment that ensures VHF-specific barrier 
and airborne precautions.7 At least 2 cases of nosocomial 
transmission of dengue (a flavivirus) have been reported in the 
   
medical literature: one through a needlestick injury and the other 
through bone marrow transplantation. 21                        
 
 
Management of Dengue Infection:                                       
The mainstay of treatment of VHF is supportive, with careful 
maintenance of fluid and electrolyte balance, circulatory volume, and 
blood pressure. Closely monitoring vital signs to avoid shock and 
correct thrombocytopenia to avoid bleeding could be adequate for 
most patients. In some cases, surgical treatment may be needed for 
DF fever patients with complications of diffuse peritonitis. 16 Because 
in some cases intravenous fluids have not reversed hypotension and 
may have contributed to pulmonary edema, consideration should be 
given to early vasopressor support with hemodynamic monitoring. 
Mechanical ventilation, renal dialysis, and antiseizure therapy may be 
required. Intramuscular injections, aspirin, nonsteroidal anti-
inflammatory drugs, and anticoagulant therapies are contraindicated. 
Steroids are not indicated.  7            
 
Prevention and Control of Dengue Haemorrhagic Fever:  
   
Current procedures to control the disease usually include 
interrupting the breeding cycles of the mosquitos as well as the use of 
insecticides. Both are inadequate in the long term.  Global warming is 
also increasing the necessity for prevention, according to World 
Wildlife Fund spokesman Dr Paul Epstein, from Harvard Medical 
School. He warned in a November 1998 report on climate change, 
which was submitted to the United Nations, that the warming of the 
earth will cause a rise in infectious diseases including dengue, 
malaria, cholera, yellow fever, and encephalitis. 22   The Australian 
Foundation for the Peoples of Asia and the Pacific, an aid 
organisation, recently completed a three year programme using the 
mesocyclops crustacean, which is about 1 mm long and devours the 
larvae of the mosquitos that carry dengue fever. Researchers say 
that the results look promising. 22  The actual changes in the 
incidence of malaria and dengue fever would, of course, depend on 
many factors, including future patterns of social development, land 
use and urban growth, and the effectiveness of preventive measures 
such as vector control and vaccination.23 Targeted community 
cleanup campaigns, particularly those directed at discarded tires and 
solid waste, are likely to have the greatest impact on reducing the risk 
   
of dengue infection. 24 They included a public education campaign 
(targeting reducing mosquito breeding habitats) and improved solid 
waste disposal. 3  Control of dengue currently depends on controlling 
its mosquito vector. 1 The actual changes in the incidence of malaria 
and dengue fever would, of course, depend on many factors, 
including future patterns of social development, land use and urban 
growth, and the effectiveness of preventive measures such as vector 
control and vaccination. 23  N,N-diethyl-3-methylbenzamide (DEET) is 
the most effective, and best studied, insect repellent currently on the 
market. This substance has a remarkable safety profile after 40 years 
of worldwide use, but toxic reactions can occur (usually when the 
product is misused). When DEET-based repellents are applied in 
combination with permethrin-treated clothing, protection against bites 
of nearly 100% can be achieved. Plant-based repellents are generally 
less effective than DEET-based products. Ultrasonic devices, outdoor 
bug "zappers," and bat houses are not effective against mosquitoes. 
Highly sensitive persons may want to take oral antihistamines to 
minimize cutaneous reactions to mosquito bites. 24   early detection 
and diagnosis of potential dengue fever outbreaks. 3 Efforts to prevent 
transmission of infection must rely on the meticulous implementation 
   
of and compliance with strict infection control measures. Filoviruses 
and arenaviruses are highly infectious after direct contact with 
infected blood and bodily secretions. Vertical transmission of dengue 
infection in a newborn from Bangladesh was reported.25         
Laboratory and Working Staff  Infection Control:          
   Given the lack of licensed or effective therapies and vaccines 
against the HFVs, efforts to prevent transmission of infection must 
rely on the meticulous implementation of and compliance with strict 
infection control measures. Filoviruses and arenaviruses are highly 
infectious after direct contact with infected blood and bodily 
secretions. A suspected case of VHF must be immediately reported 
to the hospital epidemiologist (or infection control professional) and to 
the local or state health department. The epidemiologist (or infection 
control professional) should, in turn, notify the clinical laboratory (so 
that additional precautions are put in place) as well as other clinicians 
and public health authorities. 3 Until the Aedes mosquito can be 
effectively controlled or a cost effective vaccine developed, dengue 
can be expected to continue to escalate. 13 
 
   
Protective Measures against Nosocomial Transmission 
of HVF:   
        At least 2 cases of nosocomial transmission of dengue                      
(a flavivirus) have been reported in the medical literature: one through 
a needlestick injury and the other through bone marrow 
transplantation. These events, although rare, suggest that 
nosocomial spread may also be possible for a more feared 
flavivirus—yellow fever. 26              
 
Strict Adherence to Hand Hygiene:   
 Double gloves, Impermeable gowns N-95 masks or powered 
air-purifying respirators, and a negative isolation room with 6-12 air 
changes per hour, as required by Healthcare Infection Control 
Practices Advisory Committee standards for airborne precautions  
Leg and shoe coverings Face shields Goggles for eye protection  
Restricted access of nonessential staff and visitors to patient's  room  
Dedicated medical equipment, such as stethoscopes, glucose 
monitors, and, if available, point-of-care analyzers  
Environmental disinfection with an Environmental Protection Agency–
registered hospital disinfectant or a 1:100 dilution of household 
   
bleach. If there are multiple patients with viral hemorrhagic fever in 
one health care facility, they should be cared for in the same part of 
the hospital to minimize exposures to other patients and health care 
workersThese resources may not be possible in many health care 
facilities or in a mass casualty situation. In this case, all other 
measures should be taken and would, in combination, be expected to 
substantially diminish the risk of nosocomial spread. 3         
 
Postmortem Practices:       
  Contact with cadavers has been implicated as a source of 
transmission, trained personnel, using the same infection control 
precautions as those used to transport ill patients, handle the bodies 
of patients who die of VHF. Autopsies should be performed only by 
specially trained persons using VHF-specific barrier precautions.3 
 
Vaccine:        
  Much research has been carried out to develop a dengue 
vaccine that is safe and immunogenic against all four serotypes. 
Although many of the vaccines developed so far (live attenuated, 
chimeric, DNA, and subunit vaccines) show promising results, none 
   
are sufficiently immunogenic for routine use. A live attenuated 
tetravalent vaccine was developed by serial passage of wild type 
viruses in primary dog kidney cells or other cell types. A randomised, 
double blind placebo controlled study showed all tetravalent vaccine 
recipients to have DEN-3 viraemia, and subsequently develop DEN-3 
neutralising antibodies. Furthermore, all monovalent DEN-2, DEN-3, 
and DEN-4, and 60% of DEN-1 vaccine recipients developed 
neutralising and/or IgM antibodies. When seven formulations of 
tetravalent live attenuated dengue vaccine were evaluated, 58% of 
recipients seroconverted (neutralising antibody titre  1:10) to three or 
more serotypes after the first dose, increasing to 76% after the 
second dose. Both monovalent DEN-2 and the tetravalent vaccines 
show T-cell responses against all dengue serotypes. However, 
proliferation responses are higher to DEN-1 and DEN-3 than to DEN-
2 and DEN-4, whereas cytotoxic T-lymphocyte responses are higher 
to DEN-2 and DEN-3 than to DEN-1. 4  So   It is reasoned, therefore, 
that any vaccine should induce solid immunity to all 4 serotypes.  In 
neonates the antibodies to dengue virus disappeared in the first year 
of life. So the most appropriate age for vaccination with a live-
attenuated dengue vaccine in an endemic area is one year of age. 27                         
   
 
Travelers: 
The most common tropical infections in travellers who have 
returned from a tropical country include malaria, enteric fever, viral 
hepatitis, and dengue fever. Malaria is by far the single most 
important cause of fever in a recent traveller from the tropics. As 
falciparum malaria has the potential to be rapidly fatal and is curable 
with appropriate treatment, this diagnosis must be a primary 
consideration in such patients.28 Travellers may unwittingly be 
infected with dengue virus because transmission is maintained even 
between epidemics; malaria should be ruled out in those returning 
with symptoms from an endemic area. In Australia and Germany up 
to 8% of travellers returning with febrile illnesses were found to have 
dengue. Because the incubation period can vary from 3 to 14 days 
(typically between 5 and 7 days) and viraemia can persist up to 
12 days (typically 4 to 5 days), dengue can be ruled out if symptoms 
begin more than 2 to 3 weeks after the patient has left an endemic 
area or if the fever lasts more than two weeks. Nevertheless, dengue 
haemorrhagic fever and dengue shock syndrome are rare in 
   
travellers; those with a history of dengue should be advised to protect 
themselves well from mosquitoes when travelling to endemic areas.13  
 
 
 
 
OBJECTIVES OF THE STUDY 
 
1.1.   General objective: 
To study the prevalence and clinical criteria predicting 
diagnosis and outcome of dengue viral infection among patients with 
acute febrile illnesses seeking healthcare in Sudan. The ultimate goal 
is to assist healthcare providers in the differential diagnosis of malaria 
and provide evidence in order to avoid over diagnosis of malaria in 
Sudan. 
 
1.2.     Specific objective: 
1.2.1.  To determine the prevalence of Dengue Fever 
among the acute febrile illnesses.  
   
1.2.2.  To identify the clinical criteria predicting diagnosis 
of Dengue Fever, particularly for the differential 
diagnosis from malaria.  And the predictors of 
outcome will be studied. 
1.2.3.  To see if co-infection with other febrile illnesses 
(e.g. malaria) will affect the course of disease. 
 
1.3.   Secondary objectives (optional):  
These are subsidiary objectives that could be studied during the 
course of the project but are not the main objectives of the study.   
  
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
Chapter Two 
2- MATERIALS AND METHODS 
 
2.1.    Study area: 
This is a hospital-based study that will be carried out in 
Khartoum Teaching Hospital. This is the main and biggest hospital 
in Sudan and patients from all over the country use to come and 
treated there. Both outpatients and inpatients with acute febrile 
illnesses will be candidates for the study.  
2.2.  Study subjects: 
 This is a hospital based descriptive case-control study. 
Inclusion criteria: 
1) Acute fever of less than two weeks duration. 
   
2) With or without encephalopathy or unrousable coma. 
3) Age 15-60 years old. 
Exclusion criteria:  
4) Fever due to known underlying infection e.g. diabetic septic foot 
or a vascular lesion. 
5) Comatose or drowsy patients following renal failure or there 
metabolic disease. 
6) Patients on antiviral treatment.  
7) Patients with chronic febrile illness > 2 weeks.     
2.3.  Study design:     
This is an ambidirectional design (case-control) to allow for 
studying prevalence and determinants. All eligible patients        
(adults > 18 years) will be enrolled  till completing the sample size. 
They will be subjected to clinical examinations, laboratory 
investigations, constituting the control group, regarding the clinical 
criteria predicting diagnosis and outcome. 
 
2.4. Data collection methods, instruments used, 
measurements: 
2.4.1. The instruments used for data collection:  
   
A written consent will be obtained from all patients participating 
in the study. A detailed questionnaire (attached) will be filled for every 
patients in the study including data about the illness including the 
onset and symptomatology and detailed clinical examinations looking 
and recording all signs initially and during follow up. General 
investigations for acute febrile illnesses will be carried out including 
ICT for malaria. Serum of 3ml sample will be collected in blood 
collection tubes and will be screened for IgM and IgG antibodies of 
the dengue virus. 
Student t test will be used to compare the study and the control 
groups. 
2.4.2. Techniques: 
History taking. 
Physical examinations. 
Rapid  test for screening for IgM  and IgG Antibodies  for the 
dengue virus. 
Using SD BIOLINE Dengue IgG/ IgM rapid test, this is a solid 
phase immunochromotographic assay for the rapid, qualitative and 
differential detection of IgG and IgM antibodies to Dengue virus in 
human serum, plasma or whole blood. This test is intended for 
   
professional use as aid in the presumptive diagnosis between primary 
and secondary infection. This test can also detect all 4 Dengue 
serotypes by using a micture of recombinant Dengue envelope 
proteins. Dengue IgG/ IgM test strip has 3 pre-coated line, "G" (Test 
line for Dengue IgG), "M" (Test line for Dengue IgM) and "C" (Control 
line) on the surface of the strip. All three lines in result window are not 
visible before applying any samples.        
2.4.3. Study definitions: 
 Case definition: 
2.4.4. Adult patients with acute febrile illness of less than two weeks 
duration.  
 
2.5. Data management and statistical analysis:  
After designing the master-sheet, all variables were introduced 
into the computer using D-base III for data entry. Consistency checks 
and analysis was carried out using Statistical Package for Social 
Sciences (SPSS).  
 
2.6.  Implications of study results on disease control: 
   
2.6.1.  Expected results and potential contribution of the project 
to the relevant control program viral infections are usually not looked 
for or investigated in patients with acute febrile illnesses or 
encephalitis and only considered by exclusion of other illnesses. 
There might be a reason for a lot of delay in treating infections 
resulting from these viral infections and therefore a lot of morbidity 
and mortality.  
2.6.2. Mechanisms to ensure implementation of research results in 
the health policy of the concerned control program of the ministry of 
health. National endorsement will be obtained from the federal 
ministry of health. The results and the recommendations of the study 
will be presented to the health officials.  
 
2.7. Areas of integration of research activities: 
All these data and results will be available to the ministry of 
health for implementation. 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
Chapter Three 
3-  RESULTS 
 
Patient Demographics:  
Age and Sex distribution  
  The mean age of patients in the study group (Fig 1) and the 
control (Fig 2) was 32.49 and 29.54 years respectively. 57% of them 
were males and 43% were females (Fig 3) while all the control groups 
were males. The IgM antibody was detected in (81.8%) of the study 
   
group between the age15-45 years (Table1), no sex difference 
regarding IgM positive group was detected (Table 2). 
 
Residence  
50.6% of the study group and 49.4% of the control resided in 
Khartoum area. While 48.3% and 51.7% for the study group and 
control resided out side Khartoum area respectively. Positive IgM 
patients were noticed to be from Khartoum area. 
Housewives, and student had high positive results for IgM 45% 
and 36.4% respectively (Table 3).  
 
Headache:  
 (88%) of the patients presented complaining of headache        
(Fig 4), 11 of them (100%) had positive IgM antibodies for dengue 
virus (Table 4). 
Bodyaches:  
85 (79,4%) patients of the study group complained of 
generalized body aches, 10 (11.8%) of them proved to be positive for 
IgM . this is consistent with (90.9%) of total positive IgM (Table 5). 
Neck pain: 
   
(43.9%) of the study group patients complained of neck pain, 
only 7 (63.6% of total positive IgM) of them discovered to have 
positive IgM antibodies (Table 6). 
Cough: 
        Cough was not a common complain in this study group, but we 
noticed that all the study groups, that proved to be positive for IgM 
had complained of cough. (100% of IgM positive) 
 
 
 
Nausea and vomiting:   
Constituted complain of (48.6%) patients, with only 7 (63.6% 
total positive IgM) of  them found to be positive for IgM (Table 7). 
Retro-orbital pain: 
Only 24 (22%) patients gave history of retro-orbital pain,               
3 (27.3% of total positive IgM ) of them showed serological evidence 
of IgM antibodies (Table 8). 
Photophobia : 
Constituted complain of 27(25.2%) patients with only 3 (27.3% 
of total positive IgM) of them found to be positive for IgM (Table 9). 
   
Diarrhea: 
17 (15.9%) patients complained of diarrhea, only 3 of them 
(27.3% of total positive IgM) discovered to have positive IgM 
antibodies .(Table 10) 
Fever  : 
  (68.5%) of the patient their temperature ranges between (38-
38.5 C°), seropositive (IgM) patient temperature was between (37.7-
38.7 C°) (Fig 5).  
 
 
Lymphadenopathy:   
Enlarged lymphnodes, were detected in most of the patients 
(106). 11 (100% of total positive IgM) of them had positive IgM 
antibodies (Table 11). 
Total white blood count (TWBC): 
Most of the patients of the study group (81 pts) had their total 
white blood count less than 5.000 per micro liter, 8 of them had 
positive serology for IgM antibody (72.7% of total positive IgM),  
Immunoglobulin M:  
   
 Only 11 (10.28%) of patients their serum showed a positive 
test for IgM (Fig 6). 
Immunoglobulin G: 
Was found to be negative for all patients and the control group 
in the study. 
 
 
 
 
 
 
Table 1:  Age distribution in relation to positive IgM antibody 
 
IgM Years  
+ve -ve 
Total 
15-30 6 (54.5%) 54 (56.3%) 60 (56.1%) 
31-45 3 (27.3%) 36 (37.5%) 39 (36.4%) 
46-60 2 (18.2%) 6 (6.3%) 8 (7.5%) 
 
 
   
 
Table 2:  Sex distribution in the study and control group  
 
  CASES Total 
  Study group Control  
 Male 61 (57.0%) 107 (100.0%) 168 (78.5%) 
 Female 46 (43.0%)  46 (21.5%) 
 
 
 
 
Table 3:  Residence distribution in the study and control 
group: 
 
GROUP 
Area  
CASES CONTROL 
Total 
 In Khartoum  
79 (50.6%) 77 (49.4%) 156 (100.0%) 
Out Khartoum 28 (48.3%) 30 (51.7%) 58 (100.0%) 
 
   
 
Table 4:   Headache distribution in the study and control group 
 
 IgM Total 
 +ve -ve  
Headache 
11 (100.0%) 83 (86.5%) 94 (87.9%) 
No headache  13 (13.5%) 13 (12.1%) 
 
 
 
Table 5:  Bodyaches distribution in the study group with and 
without IgM  
 
 IgM Total 
 +ve -ve  
Bodyaches  10 (90.9%) 75 (78.1%) 85 (79.4%) 
No bodyaches  1 (9.1%) 21 (21.9%) 22 (20.6%) 
 
 
   
Table 6:  Neck pain distribution in the study group with and 
without IgM  
 
 
IgM 
Total 
 +ve -ve  
Neck pain 7 (63.6%) 40 (41.7%) 47 (43.9%) 
No neck pain 4 (36.4%) 56 (58.3%) 60 (56.1%) 
 
 
 
Table 7:  Nausea and vomiting distribution in the study group 
with and without IgM  
 
 IgM Total 
 +ve -ve  
 Nausea / vomiting 7 (63.6%) 45 (46.9%) 52 (48.6%) 
 No nausea / vomiting 4 (36.4%) 51 (53.1%) 55 (51.4%) 
 
 
 
   
Table 8:   Retro-orbital pain distribution in the study group with 
and without IgM  
 
 IgM Total 
 +ve -ve  
 Retro-orbital pain 3 (27.3%) 21 (21.9%) 24 (22.4%)
 No retro-orbital pain 8 (72.7%) 75 (78.1%) 83 (77.6%)
 
 
 
 
Table 9:  Photophobia distribution in patient with & without IgM 
antibody  
  
 IgM Total 
 
+ve 
-ve  
 Photophobia 3 (27.3%)  24 (25.0%) 27 (25.2%) 
 No photophobia 8 (72.7%) 72 (75.0%) 80 (74.8%) 
 
 
   
Table 10:  Diarrhea distribution in the study group with & without 
IgM antibody  
 
 IgM Total 
 +ve -ve  
Diarrhea 
3 (27.3%) 14 (14.6%) 17 (15.9%) 
No diarrhea 8 (72.7%) 82 (85.4%) 90 (84.1%) 
 
Table 11:  Lymphadenopathy distribution in the study group with 
and without IgM antibody  
 
IgM  
+ve -ve 
Total 
Lymphadenopathy 11 (100.0%) 95 (99.0%) 106 (99.1%)
No lymphadenopathy  1 (1.0%) 1 (.9%) 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
Chapter four 
4-  DISCUSSION 
 
This is a prospective hospital-based case control study that 
was carried out in Khartoum Teaching Hospital in the period from 
February 2004 to August 2004. 
In this study, the distribution of age of patients and control was 
between 15-60 years. The age group of 15-45 years was the most 
affected and had significant anti Dengue IgM antibodies in other 
studies children were reported to be the most affected group 9. This 
study was done in emergency and accident of Khartoum hospital 
   
where most of patients were adult and children were excluded from 
this study which considerated individuals older than 15 years.   
Cough (100%), headache (87.9%), and myalgia (79.4%) 
remained the most complains of the febrile patients selected for this 
study. Interestingly these complain significantly coincided with the 
presence IgM antibody against Dengue antigens. These symptoms 
were common with other febrile illnesses that dominate the 
emergency and accident unit. The other symptoms were less 
frequently detected  (nausea / vomiting 48.6%, neck pain 43%, 
photophobia 25.2%, retro-orbital pain 22.4%, diarrhea15.9%). In the 
study done in Egypt, the main complain of Dengue fever were 
headache myalgia and retro-orbital pain and they were difficult to 
differentiate from other febrile illnesses especially malaria and 
influenza 1. 
The grades of Fever in the study group was ranged between 
37-39.2 C°, most of patient (68.5%) their temperature range between 
38-38.5 C°. 
No sex difference was noticed regarding IgM positive group, 
indicating no gender preference for Dengue infection. 
   
In this study no hemorrhagic features were observed, and this 
may augment the hypothesis that African ethnic group’s were more 
resistant to hemorrhagic fever. They may be immuned against severe 
hemorrhagic fever 3.  In this study all patients recovered within 1-2 
weeks with supportive treatment.  
The clinical examination of the studied patient showed 
lymphadenopathy (cervical, submandibular), in 100% of the study 
group who had significant IgM titer against Dengue. 
In other patients who did not react with Dengue antibody 99% 
also had lymphadenopathy. So other causes of lymph node 
enlargement are highly possible in the tropical areas. 
Non of study group or the control group had IgG detected 
antibody against Dengue in this study this result disagree with 
previous study that done in Sudan during an outbreak of acute febrile 
illness occurred between August and September 1989 in the 
Northern Province of Sudan that coincided with a high phlebotomone 
density. In that study 185 febrile individuals studied were investigated 
and tested for IgG and IgM antibody against arboviruse using enzyme 
immunoassay (EIA). Prevalence of IgG antibody was 59% for West 
Nile (WN), 53% for Sandfly Fever Sicilia (SFS), 32% for Sandfly 
   
Fever Naples (SFN), 39% for Yellow Fever (YF), 24% for dengue 
(DEN-2), 23% for Rift Valley Fever (RVF), 12 for Chikungunya (CHIK) 
and 5% for Crimean-Congo Hemorrhagic fever (CCH) viruses 29. The 
prevalence of IgM antibody to SFN was 24% while it was 5% for the 
other viruses. They use ELISA for detection, but in our study we use 
a new rapid test  (SD BIOLINE Dengue IgG/ IgM), so we suggest to 
screen a larger sample number to assure validation of this new rapid 
test.  
The prevalence of IgM in our study was 10.25%, while in that 
studies was only 5%, these slight differences could be attributed to 
the seasonal variation in the disease prevalence 6.  
The frequency of recent infection (IgM) was estimated to be 
9.8% in study done in Salvador 2000, which coincided with our study 
finding. But in the study done by joao Siqueira in central Brazil 
seroprevalence of dengue was 29.5% . 
Another study in Sudan, that was carried out on patients with 
cerebral malaria concluded that a significant number of cerebral 
malaria patients had antibodies of IgM class to Dengue virus and 
West Nile virus that was more significant than in control group 
(normal individuals) 30.  
   
 
 
 
 
 
 
 
 
CONCLUSION 
 
• This is a hospital-based prospective case control study that was 
carried out in Khartoum Teaching Hospital in the period (Feb 
2004 -Aug2004). Both outpatients and inpatients with acute 
febrile illnesses will be candidates for the study.  
• This study aimed to determine prevalence of dengue infection, 
and pattern of clinical presentation, among febrile Sudanese 
persons who sought medical advice.  
• The mean age of the study group and control was 32.49 and 
29.4 years, 57 % were male, and 43% of them were females, all 
   
the control group were males. No significant sex difference 
between positive IgM group.  
• The study showed that possible presentions of this virus are 
high grade fever (37-38.5 c°), cough (100%), headache (100%), 
myalgias (90.9%) and neck pain (63.3%), while diarrhoea retro-
orbital, and photophobia constitutes only (27.3%) are less 
common presentations in this study. lymphadenopathy (cervical 
and submandibular) was detected in most of the study group 
(99.1%)  and all IgM positive group , raising the high possibility 
of other causes rather than dengue virus.  
• No hemorrhagic manifestations among studied group were 
detected and all patients recovered spontaneously with in 1-2 
week’s duration. 
• IgM was detected in 10.28% of the study group, but no IgG was 
detected for both control and the study group, indicating primary 
infection is commoner than secondary infection in this study.  
 
 
 
   
 
 
 
 
 
 
 
RECOMMENDATIONS 
 
1. There might be a lot of delay in treating infections resulting from 
dengue viral infection and therefore a high morbidity and 
mortality. Dengue diagnosis should be considered in patient 
presented with febrile illness after exclusion of malaria. 
2. Increasing the awareness of the public health and patients 
regarding these infections, and medications for viral disease will 
be availed and registered in the medical supplies to be 
affordable for these patients. 
3. Facilities for diagnosis and control of viral infections should be 
established. 
   
4. A large studies should be conducted to determine the extent of 
these viral infections.  
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Questionnaire
The prevalence of viral infections (WNF, HSV, Dengue) among acute febrile illn
         No:…
Personal Data: 
Name…………………..... Occupation………………..…….Sex  M……..F……
Residence……………….. Marital status……………………Age…………………
Address…………………. Tribe…………………………….. Tel…………………
Symptoms:                                                                                    Yes                    
Headache……………………………………………………………………………
Body aches…………………………………………………………………………
Photophobia………………………………………………………………………
Neck pain …………………………………………………………………………
Nausea & vomiting ………………………………………………………………
Retro-orbital pain …………………………………………………………………
Diarrhea ……………………………………………………………………………
Cough ………………………………………………………………………………
Convulsions…………………………………………………………………………
Loss of consciousness………………………………………………………………
Unsteadiness ………………………………………………………………………
Hallucination………………………………………………………………………
Others………………………………………………………………………………
Past History: 
Hypertension………………………………………………………………………
Diabetes……………………………………………………………………………
Meningitis…………………………………………………………………………
Encephalitis…………………………………………………………………………
Malaria within the last three months………………………………………………
Trauma……………………………………………………………………………
Alcohol……………………………………………………………………………
Others………………………………………………………………………………
   
 
 
